Abstract
Hypoglycemic events during sulfonylureas (SUs) treatment are clinically important. We assessed the prevalence of hypoglycemia in patients with type 2 diabetes mellitus (T2DM) treated with SUs in a real-world setting in the Eastern Europe, Middle East, and Africa (EEMEA) region.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
